Xtandi

Essa abandons sole clinical-stage drug after falling short against Xtandi in phase 2 trial
Fierce Biotech
Sun, 11/3/24 - 10:17 pm
Essa Pharma
prostate cancer
masofaniten
Xtandi
Astellas
Pfizer
Pfizer's cancer drug combo improves overall survival in late-stage study
Reuters
Thu, 10/10/24 - 09:59 am
Pfizer
Talzenna
Xtandi
prostate cancer
J&J's Erleada prevails over Astellas, Pfizer’s Xtandi in real-world prostate cancer study
Fierce Pharma
Wed, 10/2/24 - 09:50 pm
JNJ
Erleada
prostate cancer
Astellas
Pfizer
Xtandi
European Commission approves Astellas’ drug for expanded prostate cancer Treatment
Outsourcing Pharma
Thu, 04/25/24 - 05:59 pm
Astellas
Xtandi
Europe
prostate cancer
Xtandi cleared by FDA for earlier-stage prostate cancer
Pharmaphorum
Fri, 11/17/23 - 10:10 am
Pfizer
Astellas
Xtandi
prostate cancer
FDA
EU clears review of Xtandi in earlier-stage prostate cancer
Pharmaphorum
Wed, 09/13/23 - 06:02 pm
EMA
Europe
Astellas
Pfizer
prostate cancer
Xtandi
Astellas withdraws lawsuit challenging Medicare drug price negotiation plans
Reuters
Thu, 09/7/23 - 10:44 am
Astellas
Medicare
prostate cancer
Xtandi
drug pricing
Inflation Reduction Act
Astellas to withhold prostate cancer drug from contract pharmacies
Beckers Hospital Review
Thu, 07/6/23 - 10:03 pm
Astellas
340B
Xtandi
prostate cancer
Pfizer, Astellas' Xtandi combo cuts risk of death by 58% in prostate cancer patients
Seeking Alpha
Mon, 05/1/23 - 10:13 am
Pfizer
Astellas
Xtandi
prostate cancer
clinical trials
Most-clicked pharma news for week ending March 25: PTC Therapeutics CEO retires and Novartis' Zolgensma shows sustained efficacy
CP Wire
Sun, 03/26/23 - 03:44 pm
PTC Therapeutics
Novartis
Zolgensma
SMA
Novo Nordisk
Ozempic
obesity
diabetes
Baxter
M&A
Celltrio
Thermo Fisher
Pfizer
Astellas
Xtandi
NIH
Most-clicked pharma news for week ending March 25: PTC Therapeutics CEO retires and Novartis' Zolgensma shows sustained efficacy
Sun, 03/26/23 - 03:36 pm
PTC Therapeutics
Novartis
Zolgensma
SMA
Novo Nordisk
Ozempic
obesity
diabetes
Baxter
M&A
Celltrio
Thermo Fisher
Pfizer
Astellas
Xtandi
NIH
US again spurns march-in campaign to slash cost of Pfizer, Astellas' Xtandi
Fierce Pharma
Wed, 03/22/23 - 11:19 am
Pfizer
Astellas
Xtandi
prostate cancer
drug pricing
NIH
march-in rights
ASCO GU: Pfizer touts Talzenna's strong showing in PARP prostate cancer battle with AstraZeneca, J&J
Fierce Pharma
Fri, 02/17/23 - 09:36 am
ASCO GU
Pfizer
Astellas
Xtandi
prostate cancer
Lawmakers again urge the Biden administration to use federal law to widen access to a cancer drug
Stat
Wed, 01/11/23 - 10:51 am
cancer
oncology
Joe Biden
Astellas
Xtandi
prostate cancer
Pfizer’s PARP inhibitor combo treatment passes primary endpoint — but details are slim
Endpoints
Tue, 10/4/22 - 11:06 am
Pfizer
Xtandi
Talzenna
PARP inhibitors
Medivation
clinical trials
prostate cancer
'March-in' battles heat up as nonprofits petition HHS on 6 drugs as earlier petition awaits decision
Endpoints
Mon, 03/28/22 - 10:08 am
HHS
Bayh-Dole Act
drug pricing
Pfizer
Gilead Sciences
Xtandi
Paxlovid
Epclusa
Descovy
insulin
March-in campaign on Pfizer's prostate cancer med Xtandi gets congressional backing. Will it matter?
Fierce Pharma
Tue, 02/22/22 - 11:17 pm
Pfizer
Astellas
prostate cancer
Xtandi
NIH
ESMO: Pfizer, Astellas' latest Xtandi survival data may shore up prostate cancer lead over J&J
Fierce Pharma
Sat, 09/18/21 - 08:26 pm
ESMO
Pfizer
Astellas
Xtandi
prostate cancer
clinical trials
ASCO: Pfizer, Astellas show Xtandi helps early prostate cancer patients live longer
Fierce Pharma
Thu, 05/14/20 - 10:15 am
ASCO 2020
Pfizer
Astellas
Xtandi
castration-resistant prostate cancer
Pfizer and Astellas Report Positive OS Data in Prostate Cancer Study
BioSpace
Tue, 02/11/20 - 11:45 pm
Pfizer
Astellas
prostate cancer
metastatic castration-resistant prostate cancer
Xtandi

Pages